Latest news with #ISO10993
Malaysian Reserve
24-06-2025
- Business
- Malaysian Reserve
Smart Automation Meets Medical Innovation: ICP DAS & ICP DAS-BMP at Manufacturing World Tokyo 2025
HSINCHU, June 24, 2025 /PRNewswire/ — ICP DAS and its biomedical business unit, ICP DAS-BMP, are pleased to announce their participation in Manufacturing World Tokyo 2025, one of Asia's premier industrial trade shows, held from July 9–11, 2025, at Makuhari Messe, Chiba, Japan. ICP DAS will showcase its latest advancements in energy management, industrial automation, and IoT integration. Highlights include the PM series smart power meters, PMC series intelligent controllers, and IoTstar cloud management software—tools that help enterprises monitor and optimize energy use. Also featured will be remote I/O modules, as well as the tGW series Modbus TCP/RTU gateways, tSH series serial port converters, and DL-10 series data loggers—offering scalable solutions for industrial environments. ICP DAS-BMP will present its growing portfolio of medical-grade TPU (thermoplastic polyurethane) materials for short-term use and implantation periods of up to 90 days. The highlight is the Engineering Arothane™ EARP-35X2 series, an aromatic TPU developed as an auxiliary material for orthodontic treatment. Known for its mechanical strength, dimensional stability, and excellent biocompatibility, it ensures dependable performance in healthcare. Also on display will be TPU pellets specifically tailored for invasive catheters and stents, guidewire coatings, Luer-Lock connectors, and radiopaque medical devices. With excellent processability, mechanical properties, and ISO 10993 compliance, they offer flexible material solutions for a wide range of medical product development needs. Drawing on three decades of automation expertise from ICP DAS, ICP DAS-BMP integrates material science with smart manufacturing. Its ISO 13485 certification and dedicated laboratories ensure strict quality control and responsive support, including small-quantity custom orders. Visit ICP DAS and ICP DAS-BMP at Hall 4, Booth No. 22-39, to explore solutions driving smart factories and healthcare innovation. About ICP DAS and ICP DAS-BMP Founded in 1993, ICP DAS is a global leader in industrial automation, delivering solutions for Industry 4.0 and the Industrial Internet of Things (IIoT). Its hardware and software offerings help businesses boost productivity, energy efficiency, and data connectivity. Its biomedical business unit, ICP DAS-BMP, specializes in medical-grade TPU development and manufacturing. With ISO 13485 certification, advanced laboratories, and smart factory capabilities, it delivers high-performance TPU materials that meet the demands of medical applications. Together, the two companies serve industrial and biomedical markets with flexibility and quality. For more information, visit and
Korea Herald
24-06-2025
- Business
- Korea Herald
Smart Automation Meets Medical Innovation: ICP DAS & ICP DAS-BMP at Manufacturing World Tokyo 2025
HSINCHU, June 24, 2025 /PRNewswire/ -- ICP DAS and its biomedical business unit, ICP DAS-BMP, are pleased to announce their participation in Manufacturing World Tokyo 2025, one of Asia's premier industrial trade shows, held from July 9–11, 2025, at Makuhari Messe, Chiba, Japan. ICP DAS will showcase its latest advancements in energy management, industrial automation, and IoT integration. Highlights include the PM series smart power meters, PMC series intelligent controllers, and IoTstar cloud management software—tools that help enterprises monitor and optimize energy use. Also featured will be remote I/O modules, as well as the tGW series Modbus TCP/RTU gateways, tSH series serial port converters, and DL-10 series data loggers—offering scalable solutions for industrial environments. ICP DAS-BMP will present its growing portfolio of medical-grade TPU (thermoplastic polyurethane) materials for short-term use and implantation periods of up to 90 days. The highlight is the Engineering Arothane™ EARP-35X2 series, an aromatic TPU developed as an auxiliary material for orthodontic treatment. Known for its mechanical strength, dimensional stability, and excellent biocompatibility, it ensures dependable performance in healthcare. Also on display will be TPU pellets specifically tailored for invasive catheters and stents, guidewire coatings, Luer-Lock connectors, and radiopaque medical devices. With excellent processability, mechanical properties, and ISO 10993 compliance, they offer flexible material solutions for a wide range of medical product development needs. Drawing on three decades of automation expertise from ICP DAS, ICP DAS-BMP integrates material science with smart manufacturing. Its ISO 13485 certification and dedicated laboratories ensure strict quality control and responsive support, including small-quantity custom orders. Visit ICP DAS and ICP DAS-BMP at Hall 4, Booth No. 22-39, to explore solutions driving smart factories and healthcare innovation. About ICP DAS and ICP DAS-BMP Founded in 1993, ICP DAS is a global leader in industrial automation, delivering solutions for Industry 4.0 and the Industrial Internet of Things (IIoT). Its hardware and software offerings help businesses boost productivity, energy efficiency, and data connectivity. Its biomedical business unit, ICP DAS-BMP, specializes in medical-grade TPU development and manufacturing. With ISO 13485 certification, advanced laboratories, and smart factory capabilities, it delivers high-performance TPU materials that meet the demands of medical applications. Together, the two companies serve industrial and biomedical markets with flexibility and quality.
Cision Canada
10-06-2025
- Business
- Cision Canada
Spiderwort Biotechnologies Inc. Receives Health Canada Investigational Testing Authorization for Next-Generation Dermal Filler
® represents the next-generation in medical aesthetics leveraging Spiderwort Biotechnologies regenerative cellulose-based technology platform OTTAWA, ON, June 10, 2025 /CNW/ - Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced it has received Investigational Testing Authorization (ITA) from Health Canada for CelluJuve ®, its next-generation cellulose-based dermal filler currently under development. The ITA enables Spiderwort Biotechnologies Inc. to initiate a human clinical trial in Canada to evaluate the safety and performance of CelluJuve ® for tissue augmentation and rejuvenation. The planned clinical trials will evaluate the interaction between CelluJuve® and human tissues. This authorization follows the company's successful completion of ISO 10993 biocompatibility testing and human skin safety testing for CelluJuve ®. "Receiving the Investigational Testing Authorization from Health Canada is a critical inflection point in our mission to transform the landscape of regenerative medicine in multiple categories," said Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies Inc."This achievement validates our rigorous development approach and accelerates our path toward bringing CelluJuve ® to patients and clinicians who are seeking innovative alternatives in dermal fillers. We're excited to begin the clinical evaluation phase and demonstrate the potential benefits of our cellulose-based technology Aerocel™ in medical aesthetics and beyond." "As a board certified dermatologist with extensive experience in facial aesthetics, I am encouraged by CelluJuve®'s innovative approach to tissue augmentation." Dr. Joely Kaufman, MD, FAAD, member of Spiderwort's Clinical Advisory Board, "The preliminary data suggests that this cellulose-based technology could potentially offer an alternative method to address the signs of facial aging. I look forward to seeing the clinical results of this promising biomaterial." CelluJuve ® is under development to provide medical professionals with a cellulose-based alternative to current dermal fillers. The product is designed to work with the body to create a natural look and feel by providing a framework for collagen deposition, with the initial target for Spiderwort Biotechnologies Inc.'s research being nasolabial fold remediation. The company's state-of-the-art ISO 5 cleanroom facility, announced earlier this year, will support the production of medical-grade CelluJuve ® for the upcoming trials, ensuring all materials meet the quality standards required for human use. "CelluJuve® is a testament to where bold science can lead," said Dr. Andrew Pelling, Chief Science Officer at Spiderwort Biotechnologies Inc."We're demonstrating how plant-derived biomaterials can become a powerful foundation to address a variety of medical needs. These recent and critical regulatory advancements in our product portfolio reveal how nature inspired innovation can unlock entirely new frontiers in rejuvenating and regenerating human tissues." CelluJuve ® is a device under development. While it has received Investigational Testing Authorization from Health Canada for clinical trials, it is not yet approved by Health Canada or the U.S. Food and Drug Administration (FDA) for commercial use, and it is not available for sale. The safety and effectiveness of CelluJuve ® in humans has not been fully established and will be evaluated in upcoming clinical trials. For more information about Spiderwort Biotechnologies and CelluJuve ®, please visit About Spiderwort Biotechnologies Inc. Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort's biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at
Time of India
02-06-2025
- Health
- Time of India
Sree Chitra completes six new tech transfers
Thiruvananthapuram: The Sree Chitra Tirunal Institute for Medical Sciences (SCTIMST), which has a long history of technology transfers and commercialisation of medical devices and biomaterials, made six new technological transfers, including a deep brain stimulator. The indigenous development of a deep brain stimulator is for managing movement disorders such as Parkinson's disease and dystonia. The project was initiated with support from the technical research centre of the department of science and technology, Govt of India. Another technology transfer made is the "mice transfer and enrichment box-tunnel system with securing gates." Laboratory mice constitute over 87% of the total laboratory animals used in research. The test results using this system show that it can not only reduce stress during handling and cage shifting of animals but also act as an enrichment material inside the cage to reduce fighting behaviour and other unwanted behaviour observed in laboratory mice. The "plasma proteins fibrinogen, thrombin albumin and IVIG" technology is a small-scale fractionation of plasma to obtain four plasma proteins: Fibrinogen, Thrombin, Albumin, and Immunoglobulin. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like 5 Books Warren Buffett Wants You to Read In 2025 Blinkist: Warren Buffett's Reading List Undo Fibrinogen concentrate and thrombin are two major proteins of blood plasma. It has enormous potential in the preparation of wound healing matrices, tissue adhesives, and haemostats. Albumin is used as a replacement therapy in cases where blood volume loss occurs, liver diseases, and cancer. Two main uses for IVIG are as replacement therapy in primary or acquired antibody deficiency disorders and as immunomodulatory agents in patients with autoimmune or inflammatory conditions, and it has enormous potential. The "intracranial and subdural electrodes" technology are critical tools in neurology essential for electrocorticography and targeted cortical stimulation. But globally sourced electrodes are prohibitively expensive, limiting access in many parts of the world. To address this need, an indigenous development initiative was launched. The "chitosan-based antioxidant polymeric wound dressings for controlled antibiotic delivery" is an advanced wound care material intended for treating chronic and infected wounds. The last technology transfer made was on the reference materials for biological evaluations. For meeting the regulatory requirements in biocompatibility evaluations, as per international standards ISO 10993, a proof of concept project under TRC was completed at calibration cell, SCTIMST, for the development and standardisation of in-house reference biomaterials.
Cision Canada
29-04-2025
- Business
- Cision Canada
Spiderwort Biotechnologies Inc. Announces Status of Biocompatibility Testing for CelluJuve®
Cellulose dermal filler achieves critical biocompatibility milestones, paving the way for clinical trials OTTAWA, ON, April 29, 2025 /CNW/ - Spiderwort Biotechnologies Inc., a pioneering biotechnology company focused on cellulose-based regenerative medicine, today announced the completion of ISO 10993 biocompatibility testing and human skin safety testing for its future product family, CelluJuve ®, a series of next-generation dermal fillers. CelluJuve ® is a cellulose-based dermal filler solution being developed to provide structural support for soft tissue augmentation and rejuvenation. "The successful completion of ISO 10993 testing is a pivotal moment for Spiderwort in our advancement toward clinical trials," said Dr. Charles M. Cuerrier, CEO of Spiderwort Biotechnologies Inc. "These results help validate our innovative biotechnology platform that transforms cellulose into a medical-grade product." ISO 10993 testing is a key prerequisite for entering human clinical trials. As a complement to ISO 10993 requirements, Spiderwort Biotechnologies Inc. performed skin prick and patch testing in human subjects to further validate biocompatibility. The comprehensive testing demonstrated in non-clinical models that CelluJuve ® is: Non-toxic, non-sensitizing, and non-mutagenic Classified as a non-irritant and non-sensitizing for a diverse range of human skin types, as verified through additional human skin prick and patch testing Highly biocompatible and stable "These results represent years of technical development in transforming cellulose-based materials into medical-grade solutions," Dr. Andrew Pelling, Chief Science Officer at Spiderwort Biotechnologies Inc., "Our team has fundamentally reimagined what's possible in biomaterials, proving we can leverage plant structures in ways that are not only compatible with human tissue but offer unique advantages over traditional options. This milestone helps validate our approach and moves us closer to redefining what's possible in regenerative medicine." Throughout the assessments, Spiderwort Biotechnologies Inc. placed significant emphasis on ensuring diversity in its testing protocols. This approach ensures CelluJuve ® has the potential to benefit all skin tones, reflecting Spiderwort Biotechnologies Inc.'s commitment to inclusive development practices. "As a clinician focused on aesthetic outcomes and patient safety, I'm impressed with CelluJuve's biocompatibility profile," Dr. Jason Bloom, MD, FACS, member of Spiderwort's Clinical Advisory Board and renowned facial plastic surgeon, "The non-irritant classification and human testing results suggest CelluJuve ® could offer a compelling alternative in the dermal filler space. Physicians and patients increasingly seek new and innovative options with favorable safety profiles, and these test results position CelluJuve ® to potentially address that growing demand while offering unique structural properties for tissue augmentation and rejuvenation." Construction of Spiderwort's state-of-the-art ISO 5 cleanroom facility, announced earlier this year, has been instrumental in achieving these results, reinforcing the company's ability to transform raw cellulose materials into medical devices that meet the stringent standards necessary for human use. CelluJuve ® is a device under development. It is not approved by Health Canada or the U.S. Food and Drug Administration, and it is not available for sale. The safety and effectiveness of CelluJuve ® in humans has not been established. For more information about Spiderwort Biotechnologies and CelluJuve ®, please visit About Spiderwort Biotechnologies Inc. Spiderwort is transforming biotechnology with a platform of cellulose-based biomaterials that serve as the scaffolds for the regenerative medicine of the future. Spiderwort's biomaterials have shown promise in the treatment of spinal cord injuries and soft tissue regeneration. Spun out as a startup from the Pelling Lab, Spiderwort is led by CEO Charles M. Cuerrier and inspired by the work of CSO and TED Fellow Andrew E. Pelling. Learn more at
